Bavarian Nordic Announces Appointment of Paul Chaplin, PhD as President & CEO
Bavarian Nordic A/S has announced that Paul Chaplin, PhD has been appointed new President and CEO of the company. He replaces Anders Hedegaard who has served in this position since 2007. Mr Hedegaard leaves the company to join GN ReSound A/S as CEO.
Prior to joining Bavarian Nordic in 1999, Dr Chaplin worked in vaccine research with the Institute for Animal Health in UK and CSIRO, the Cooperative Research Centre for Vaccine Technology in Australia. In 2000, he was appointed head of research and in 2004 he was appointed Executive Vice President. Amongst others things, he has led the development programme for the Imvamue smallpox vaccine as well as been responsible for the successful collaboration on this and other vaccines with the US Government throughout the years. Since 2010 he has held the position as Division President, Infectious Diseases. Under his leadership, Bavarian Nordic received its first product approval in 2013.
Gerard van Odijk, chairman of the board of Bavarian Nordic said: "Paul Chaplin is the ideal person to lead our company at this time. As a member of our executive management team for over a decade, Paul has demonstrated excellent results and leadership at Bavarian Nordic. From his work in early research and development, to building our large-scale manufacturing infrastructure, managing government contracts and optimizing operations in our infectious disease division, and turning it into a profitable business, we welcome the opportunity to have Paul as our CEO. On behalf of the board, I would also like to express our sincere appreciation to Anders Hedegaard for his leadership throughout the last seven years. Anders has succeeded in transitioning Bavarian Nordic from a research focused biotech to an integrated biopharmaceutical company with a solid focus on organizational development and optimization. This has created a strong commercial and scientific foundation for further growth. We would like to thank Anders for his significant contribution to the company's development and we wish him all the best in his new CEO position in one of the leading life science companies in Denmark."
Paul Chaplin, President and CEO of Bavarian Nordic said: "I am very excited about my new role and the opportunity to lead Bavarian Nordic further on the growth track of commercial and clinical success that we have seen to date. We have developed into a fully-fledged, integrated business, ready to maximize the potential of new vaccines and cancer immunotherapies in the pipeline, which hold great promise."
As part of the management changes, Executive Vice President and CFO Ole Larsen will become registered manager with the Danish Business Authority.
Paul Chaplin will assume the position as President and CEO with immediate effect. He will be assisted by Anders Hedegaard over the next few weeks to ensure a smooth transition.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance